2012
DOI: 10.1177/230949901202000215
|View full text |Cite
|
Sign up to set email alerts
|

Correlation between a Bone Resorption Marker and Structural Geometry of the Proximal Femur in Osteoporotic Women Treated with Raloxifene

Abstract: purpose. To assess correlations between a bone resorption marker and the structural geometry of the proximal femur in raloxifene-treated postmenopausal women with osteoporosis. Methods. 45 postmenopausal, osteoporotic women aged 57 to 79 (mean, 67) years underwent raloxifene treatment (60 mg/day) for 12 months. Serum type-I collagen crosslinked N-telopeptide (sNTX) as the bone resorption marker was measured at baseline and 6 months, whereas hip structure analysis (HSA) parameters of the femur (neck, intertroch… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

2
13
1

Year Published

2014
2014
2019
2019

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 7 publications
(16 citation statements)
references
References 41 publications
2
13
1
Order By: Relevance
“…The decreases in the biochemical marker concentrations from baseline were statistically significant when statistical significance was reported. When reported, the mean percentage decrease in concentrations after 52 weeks of treatment with raloxifene varied from 10%31 to 38%30 for BAP and 13.5%39 to 35%29,31 for NTx. In the randomized comparative trial of raloxifene and alendronate,31 the mean percentage decreases in serum alkaline phosphatase concentrations after 52 weeks of treatment and urinary NTx concentrations after 12 weeks of treatment were less for raloxifene than alendronate (alkaline phosphatase not significant, NTx P <0.05, Table 3).…”
Section: Resultsmentioning
confidence: 99%
See 4 more Smart Citations
“…The decreases in the biochemical marker concentrations from baseline were statistically significant when statistical significance was reported. When reported, the mean percentage decrease in concentrations after 52 weeks of treatment with raloxifene varied from 10%31 to 38%30 for BAP and 13.5%39 to 35%29,31 for NTx. In the randomized comparative trial of raloxifene and alendronate,31 the mean percentage decreases in serum alkaline phosphatase concentrations after 52 weeks of treatment and urinary NTx concentrations after 12 weeks of treatment were less for raloxifene than alendronate (alkaline phosphatase not significant, NTx P <0.05, Table 3).…”
Section: Resultsmentioning
confidence: 99%
“…Findings for BMD were reported in eleven of the 15 publications, and included BMD of the lumbar spine (nine publications),29,3133,3538,40 of the femoral neck, total hip, or total neck (six publications),29,32,33,3638 or of other regions in the hip (five publications) 24,33,36,38,39. Findings were reported as the percentage change in BMD from baseline to 52 weeks or BMD at baseline and at 52 weeks in all publications.…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations